跳至主要内容
临床试验/NCT02217150
NCT02217150已完成不适用

The DFINE STAR™ Tumor Ablation Prospective Clinical Series

DFINE Inc.8 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
DFINE Inc.
入组人数
50
试验地点
8
主要终点
Change in Pain

研究概览

简要总结

Prospective clinical series to gather post tumor ablation clinical outcomes from subjects with painful spinal metastases following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The STAR™ Tumor Ablation System is indicated for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body.

排除标准

  • The device is contraindicated in subjects with heart pacemakers, or other electronic device implants.
  • The device is contraindicated in vertebral body levels C1-7.

结局指标

主要结局

Change in Pain

时间窗: 1 month

Mean change from baseline in worst pain score per NRPS at one month

次要结局

  • Change in Quality of Life(3 months)
  • Change if Quality of Life(3 months)
  • Change in Function(3 months)

研究者

发起方
DFINE Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验